PerturbAI and 10x Genomics Unveil 8 Million-Cell In Vivo CRISPR Atlas
PerturbAI and partners, including 10x Genomics, released an 8 million-cell in vivo CRISPR atlas mapping gene function across hundreds of neuronal cell types in mouse brain. This dataset leverages 10x Genomics’ single-cell analysis platform to expand causal genomics resources and could boost demand for its sequencing technology.
1. Collaboration and Atlas Release
PerturbAI emerged from stealth to publicly release the world’s largest in vivo CRISPR atlas, a dataset of 8 million brain-wide cells. The atlas maps effects of thousands of genetic perturbations across hundreds of neuronal cell types, capturing causal gene function within intact mouse brains.
2. 10x Genomics’ Technological Contribution
10x Genomics provided high-throughput single-cell sequencing and analysis tools to generate and interpret the atlas. Its technology enabled detailed resolution of cell states and genetic responses, showcasing the platform’s scalability and data quality.
3. Business Impact for 10x Genomics
This collaboration underscores demand for 10x Genomics’ products in large-scale in vivo studies and strengthens its position in causal genomics. Success of the atlas could drive new service agreements and platform sales to pharmaceutical and research partners.
4. Future Opportunities
The rich causal dataset is positioned to accelerate development of AI-driven biological models and novel therapeutics. Continued partnerships and expanded in vivo projects may further enhance 10x Genomics’ addressable market and long-term growth prospects.